Pfizer and BioNTech have signed an agreement under which the European Commission (EC) and its member states will procure over 200 million additional doses of the companies’ Covid-19 vaccine Comirnaty.

Leveraging the mRNA technology of BioNTech, the vaccine was co-developed by the company along with Pfizer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioNTech holds the marketing authorization for the vaccine in the US, the European Union (EU), UK and Canada among others while the companies jointly hold emergency use authorizations in the US.

These doses, to be supplied next year, are apart from the 450 million doses of Comirnaty agreed to be delivered next year under the deals entered earlier.

The order takes the vaccine doses to be supplied in the European Union next year to a total of over 650 million.

Pfizer noted that the parties are finalising the contractual details.

The latest option exercise is part of the deal signed by the parties in May.

Under this deal, the companies agreed to deliver 900 million vaccines starting from this month and continuing through 2023, with EC holding an option to procure up to another 900 million doses, taking it to a total of 1.8 billion doses.

If a variant shot is determined to be required and later authorised or approved, this order will also comprise modified vaccines against the Omicron variant without added charges.

In a similar agreement, the US Government procured an additional 200 million doses of the vaccine to meet the continued need for shots in the region.

Last month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) provided a positive opinion on the use of the vaccine in children aged five to 12 years.

The recommendation is based on data, which included positive findings from a randomised, controlled Phase II/III trial of the vaccine.